BostonGene will use its next-generation sequencing technologies to analyze tumor samples collected at Sylvester and help guide treatment selection accordingly.
BostonGene will contribute its genomic testing and bioinformatics capabilities to search for biomarkers and actionable targets in data from MSK's preclinical and clinical research programs.